Vibrio cholerae O139 genomes provide a clue to why it may have failed to usher in the eighth cholera pandemic.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
05 07 2022
Historique:
received: 15 09 2021
accepted: 14 06 2022
entrez: 5 7 2022
pubmed: 6 7 2022
medline: 8 7 2022
Statut: epublish

Résumé

Cholera is a life-threatening infectious disease that remains an important public health issue in several low and middle-income countries. In 1992, a newly identified O139 Vibrio cholerae temporarily displaced the O1 serogroup. No study has been able to answer why the potential eighth cholera pandemic (8CP) causing V. cholerae O139 emerged so successfully and then died out. We conducted a genomic study, including 330 O139 isolates, covering emergence of the serogroup in 1992 through to 2015. We noted two key genomic evolutionary changes that may have been responsible for the disappearance of genetically distinct but temporally overlapping waves (A-C) of O139. Firstly, as the waves progressed, a switch from a homogenous toxin genotype in wave-A to heterogeneous genotypes. Secondly, a gradual loss of antimicrobial resistance (AMR) with the progression of waves. We hypothesize that these two changes contributed to the eventual epidemiological decline of O139.

Identifiants

pubmed: 35790755
doi: 10.1038/s41467-022-31391-4
pii: 10.1038/s41467-022-31391-4
pmc: PMC9256687
doi:

Substances chimiques

Cholera Toxin 9012-63-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3864

Subventions

Organisme : Department of Health
ID : NIHR200640
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108413/A/15/D
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

mBio. 2020 Nov 10;11(6):
pubmed: 33172996
PLoS One. 2017 Jan 19;12(1):e0169324
pubmed: 28103259
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
Microb Genom. 2021 Sep;7(9):
pubmed: 34559043
Gut Pathog. 2017 Nov 6;9:60
pubmed: 29142593
Vaccine. 2020 Feb 29;38 Suppl 1:A13-A17
pubmed: 31326254
Kansenshogaku Zasshi. 1997 Oct;71(10):1037-45
pubmed: 9394556
mBio. 2016 Apr 12;7(2):e02237-15
pubmed: 27073099
Front Public Health. 2019 Jul 23;7:203
pubmed: 31396501
Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):E2010-7
pubmed: 22711841
Infect Immun. 2009 Sep;77(9):3807-16
pubmed: 19564383
Lancet. 1996 Oct 26;348(9035):1181
pubmed: 8888210
Sci Rep. 2019 Apr 10;9(1):5865
pubmed: 30971707
Indian J Med Res. 1996 Feb;103:71-3
pubmed: 8714141
Nat Genet. 2018 Jul;50(7):951-955
pubmed: 29942084
Genome Med. 2014 Nov 20;6(11):90
pubmed: 25422674
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
Emerg Infect Dis. 2000 Mar-Apr;6(2):139-47
pubmed: 10756147
mBio. 2020 Feb 11;11(1):
pubmed: 32047137
Gene. 1998 Nov 26;223(1-2):269-82
pubmed: 9858748
Bioinformatics. 2015 Nov 15;31(22):3691-3
pubmed: 26198102
Bioinformatics. 2019 Feb 1;35(3):526-528
pubmed: 30016406
J Bacteriol. 1996 Jul;178(14):4157-65
pubmed: 8763944
Emerg Infect Dis. 2003 Sep;9(9):1116-22
pubmed: 14519249
Lancet. 1998 Aug 8;352(9126):457-8
pubmed: 9708764
Vaccine. 2015 Nov 17;33(46):6360-5
pubmed: 26348402
Vaccine. 2020 Feb 29;38 Suppl 1:A46-A51
pubmed: 31345641
Infect Agents Dis. 1995 Mar;4(1):41-6
pubmed: 7728355
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6226-6231
pubmed: 30867296
Proc Int Conf Intell Syst Mol Biol. 1996;4:155-64
pubmed: 8877515
Gut. 1994 Feb;35(2):145-9
pubmed: 8307461
Nucleic Acids Res. 2019 Jun 20;47(11):5539-5549
pubmed: 31076776
J Clin Microbiol. 1997 Dec;35(12):3348-50
pubmed: 9399556
J Clin Microbiol. 1998 Jul;36(7):2149-52
pubmed: 9650989
Nature. 2019 Jan;565(7738):230-233
pubmed: 30602788
Nature. 2011 Aug 24;477(7365):462-5
pubmed: 21866102
J Infect Dis. 1994 May;169(5):1029-34
pubmed: 8169387
Lancet. 1993 Aug 14;342(8868):382-3
pubmed: 8101894
J Clin Microbiol. 1999 May;37(5):1313-8
pubmed: 10203477
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
Nucleic Acids Res. 2002 Apr 1;30(7):1575-84
pubmed: 11917018
Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15442-7
pubmed: 19720995
Microbiology (Reading). 2002 Nov;148(Pt 11):3681-3693
pubmed: 12427958
Lancet. 1993 Mar 13;341(8846):703-4
pubmed: 8095620
J Clin Microbiol. 1999 Mar;37(3):734-41
pubmed: 9986842
BMC Bioinformatics. 2010 Mar 08;11:119
pubmed: 20211023
Vaccine. 2020 Feb 29;38 Suppl 1:A31-A40
pubmed: 31395455
Euro Surveill. 2011 May 19;16(20):19870
pubmed: 21616048
Front Microbiol. 2017 Nov 16;8:2261
pubmed: 29250038
Trends Microbiol. 1997 Apr;5(4):161-5
pubmed: 9141191
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
PLoS Negl Trop Dis. 2015 Nov 12;9(11):e0004183
pubmed: 26562418

Auteurs

Thandavarayan Ramamurthy (T)

National Institute of Cholera and Enteric Diseases (NICED), Kolkata, West Bengal, India.

Agila Kumari Pragasam (AK)

Department of Clinical Microbiology, Christian Medical College, Vellore, India.

Alyce Taylor-Brown (A)

Parasites & Microbes Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, United Kingdom.

Robert C Will (RC)

Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

Karthick Vasudevan (K)

Department of Clinical Microbiology, Christian Medical College, Vellore, India.
School of Applied Sciences, Department of Biotechnology, REVA University, Bangalore, India.

Bhabatosh Das (B)

Translational Health Science and Technology Institute, Faridabad, India.

Sunil Kumar Srivastava (SK)

Swami Shraddhanand College, University of Delhi, New Delhi, India.

Goutam Chowdhury (G)

National Institute of Cholera and Enteric Diseases (NICED), Kolkata, West Bengal, India.

Asish K Mukhopadhyay (AK)

National Institute of Cholera and Enteric Diseases (NICED), Kolkata, West Bengal, India.

Shanta Dutta (S)

National Institute of Cholera and Enteric Diseases (NICED), Kolkata, West Bengal, India.

Balaji Veeraraghavan (B)

Department of Clinical Microbiology, Christian Medical College, Vellore, India.

Nicholas R Thomson (NR)

Parasites & Microbes Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, United Kingdom.
London School of Hygiene and Tropical Medicine, WC1EHT, London, United Kingdom.

Naresh C Sharma (NC)

Maharishi Valmiki Infectious Diseases Hospital, Delhi, India.

Gopinath Balakrish Nair (GB)

Rajiv Gandhi Centre for Biotechnology, Trivandrum, India.

Yoshifumi Takeda (Y)

National Institute of Infectious Diseases, Tokyo, Japan.

Amit Ghosh (A)

National Institute of Cholera and Enteric Diseases (NICED), Kolkata, West Bengal, India.

Gordon Dougan (G)

Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom.

Ankur Mutreja (A)

Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom. am872@medschl.cam.ac.uk.
Translational Health Science and Technology Institute, Faridabad, India. am872@medschl.cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH